MedPath

UVB Light and Sunscreen

Phase 4
Completed
Conditions
Vitamin D Status
Interventions
Other: Tanning spray
Other: UVB
Registration Number
NCT00818467
Lead Sponsor
Creighton University
Brief Summary

Patients need vitamin D which is normally produced in the skin in response to ultraviolet light from the sun. Vitamin D is important for calcium absorption and good bone health. Physicians have been using sunscreens to protect patients from skin cancer and the aging effects of sunlight for a least a half a century. Dermatologists have promoted sunscreen use to restrict sunlight exposure especially in white Caucasians. If this behavior is done 100% of the time when outdoors individuals may suffer from vitamin D deficiency. It is impossible to influence persons' behavior to wear sunscreens all the time when outdoors. With the use of sunless tanning agent (DHA), once a week, we can obtain a continuous sunscreen in the top layer of the skin that will not wash off, can't be removed with soap and water, or removed by perspiration. Under these circumstances we can answer the scientific question, will sunscreen use inhibit the production of vitamin D in the skin?

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • males or females
  • ages 19-50 with less than 16 oz milk per day
  • less than 10 hours of sun per week
  • no Vitamin D supplements
  • no anticonvulsants
  • no barbiturates
  • no steroids
  • no meds that increase photosensitivity
  • no granulomatous disease
  • no liver or kidney disease
  • no history of skin cancer
  • BMI less than 30
  • skin types I & II
Exclusion Criteria
  • None

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Tanning sprayTanning sprayTo characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a group of normal subjects with skin types I and II while using multiple applications of 3% DHA for five weeks.
UVBUVBTo characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a control group of normal subjects with skin types I and II who are not using 3% DHA applications.
Primary Outcome Measures
NameTimeMethod
To measure the response of 25(OH)D to 40 milliJoules of UV-B light in white Caucasians with melanoidins-sunscreen from 3% DHA in comparison to the response of control subjects who have not used 3% DHA.1 month
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Creighton University

🇺🇸

Omaha, Nebraska, United States

© Copyright 2025. All Rights Reserved by MedPath